nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—SLC6A3—malignant glioma	0.647	1	CbGaD
Maprotiline—CYP1A2—Carmustine—malignant glioma	0.0248	1	CbGbCtD
Maprotiline—HTR2C—choroid plexus—malignant glioma	0.0177	0.132	CbGeAlD
Maprotiline—HTR2A—choroid plexus—malignant glioma	0.00888	0.0662	CbGeAlD
Maprotiline—ORM1—vertebral column—malignant glioma	0.00696	0.0519	CbGeAlD
Maprotiline—SLC6A3—telencephalic ventricle—malignant glioma	0.00537	0.04	CbGeAlD
Maprotiline—HTR2C—telencephalic ventricle—malignant glioma	0.00519	0.0387	CbGeAlD
Maprotiline—HTR7—pons—malignant glioma	0.00507	0.0378	CbGeAlD
Maprotiline—HTR2A—cerebellar cortex—malignant glioma	0.00447	0.0333	CbGeAlD
Maprotiline—HTR7—telencephalic ventricle—malignant glioma	0.00417	0.0311	CbGeAlD
Maprotiline—DRD2—telencephalic ventricle—malignant glioma	0.00395	0.0294	CbGeAlD
Maprotiline—Interstitial pneumonia—Temozolomide—malignant glioma	0.00333	0.0312	CcSEcCtD
Maprotiline—Tongue discolouration—Temozolomide—malignant glioma	0.00333	0.0312	CcSEcCtD
Maprotiline—HTR2A—pons—malignant glioma	0.00316	0.0236	CbGeAlD
Maprotiline—HTR2A—vertebral column—malignant glioma	0.00314	0.0234	CbGeAlD
Maprotiline—HTR2A—telencephalic ventricle—malignant glioma	0.0026	0.0194	CbGeAlD
Maprotiline—Interstitial lung disease—Carmustine—malignant glioma	0.00235	0.0221	CcSEcCtD
Maprotiline—Sertraline—CYP2B6—malignant glioma	0.00231	0.305	CrCbGaD
Maprotiline—Interstitial lung disease—Temozolomide—malignant glioma	0.00227	0.0213	CcSEcCtD
Maprotiline—HTR2A—pineal body—malignant glioma	0.00226	0.0168	CbGeAlD
Maprotiline—HTR7—endothelium—malignant glioma	0.00224	0.0167	CbGeAlD
Maprotiline—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00214	0.02	CcSEcCtD
Maprotiline—HTR7—blood vessel—malignant glioma	0.00207	0.0154	CbGeAlD
Maprotiline—Memory impairment—Temozolomide—malignant glioma	0.00205	0.0192	CcSEcCtD
Maprotiline—Sertraline—SLC6A3—malignant glioma	0.00197	0.26	CrCbGaD
Maprotiline—Petechiae—Temozolomide—malignant glioma	0.00196	0.0183	CcSEcCtD
Maprotiline—Endocrine disorder—Temozolomide—malignant glioma	0.00194	0.0182	CcSEcCtD
Maprotiline—Coordination abnormal—Carmustine—malignant glioma	0.0017	0.0159	CcSEcCtD
Maprotiline—Coordination abnormal—Temozolomide—malignant glioma	0.00164	0.0154	CcSEcCtD
Maprotiline—Gynaecomastia—Carmustine—malignant glioma	0.00149	0.014	CcSEcCtD
Maprotiline—SLC6A3—brainstem—malignant glioma	0.00145	0.0108	CbGeAlD
Maprotiline—HTR2C—brainstem—malignant glioma	0.0014	0.0105	CbGeAlD
Maprotiline—HTR2A—endothelium—malignant glioma	0.0014	0.0104	CbGeAlD
Maprotiline—CHRM4—central nervous system—malignant glioma	0.00137	0.0102	CbGeAlD
Maprotiline—Vascular purpura—Temozolomide—malignant glioma	0.00131	0.0122	CcSEcCtD
Maprotiline—CHRM2—telencephalon—malignant glioma	0.00129	0.00963	CbGeAlD
Maprotiline—SLC6A3—telencephalon—malignant glioma	0.00129	0.00961	CbGeAlD
Maprotiline—HTR2A—blood vessel—malignant glioma	0.00129	0.0096	CbGeAlD
Maprotiline—Nasal congestion—Temozolomide—malignant glioma	0.00128	0.012	CcSEcCtD
Maprotiline—Hot flush—Temozolomide—malignant glioma	0.00125	0.0117	CcSEcCtD
Maprotiline—HTR2C—telencephalon—malignant glioma	0.00125	0.00928	CbGeAlD
Maprotiline—Menopausal symptoms—Temozolomide—malignant glioma	0.00124	0.0116	CcSEcCtD
Maprotiline—Purpura—Temozolomide—malignant glioma	0.00121	0.0114	CcSEcCtD
Maprotiline—CHRM1—telencephalon—malignant glioma	0.00118	0.00877	CbGeAlD
Maprotiline—SLC6A2—brainstem—malignant glioma	0.00117	0.00873	CbGeAlD
Maprotiline—Ataxia—Carmustine—malignant glioma	0.00114	0.0107	CcSEcCtD
Maprotiline—HTR7—brainstem—malignant glioma	0.00113	0.00842	CbGeAlD
Maprotiline—Liver function test abnormal—Carmustine—malignant glioma	0.00112	0.0105	CcSEcCtD
Maprotiline—Ataxia—Temozolomide—malignant glioma	0.0011	0.0103	CcSEcCtD
Maprotiline—CHRM4—brain—malignant glioma	0.00109	0.0081	CbGeAlD
Maprotiline—CHRM5—central nervous system—malignant glioma	0.00107	0.00798	CbGeAlD
Maprotiline—DRD2—brainstem—malignant glioma	0.00107	0.00796	CbGeAlD
Maprotiline—Muscular weakness—Carmustine—malignant glioma	0.00107	0.01	CcSEcCtD
Maprotiline—Breast disorder—Temozolomide—malignant glioma	0.00106	0.0099	CcSEcCtD
Maprotiline—CHRM3—telencephalon—malignant glioma	0.00105	0.00785	CbGeAlD
Maprotiline—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.00105	0.00987	CcSEcCtD
Maprotiline—Dysphagia—Carmustine—malignant glioma	0.00104	0.0098	CcSEcCtD
Maprotiline—SLC6A2—telencephalon—malignant glioma	0.00104	0.00775	CbGeAlD
Maprotiline—DRD2—retina—malignant glioma	0.00103	0.00768	CbGeAlD
Maprotiline—Muscular weakness—Temozolomide—malignant glioma	0.00103	0.00966	CcSEcCtD
Maprotiline—Dysphagia—Temozolomide—malignant glioma	0.00101	0.00947	CcSEcCtD
Maprotiline—HTR7—telencephalon—malignant glioma	0.001	0.00747	CbGeAlD
Maprotiline—Pancytopenia—Carmustine—malignant glioma	0.000992	0.00931	CcSEcCtD
Maprotiline—Sweating increased—Temozolomide—malignant glioma	0.000983	0.00922	CcSEcCtD
Maprotiline—HTR2C—medulla oblongata—malignant glioma	0.000979	0.0073	CbGeAlD
Maprotiline—ORM1—spinal cord—malignant glioma	0.000971	0.00724	CbGeAlD
Maprotiline—Pancytopenia—Temozolomide—malignant glioma	0.000959	0.00899	CcSEcCtD
Maprotiline—DRD2—telencephalon—malignant glioma	0.000948	0.00706	CbGeAlD
Maprotiline—Pollakiuria—Temozolomide—malignant glioma	0.000932	0.00875	CcSEcCtD
Maprotiline—Erectile dysfunction—Temozolomide—malignant glioma	0.00093	0.00872	CcSEcCtD
Maprotiline—SLC6A3—midbrain—malignant glioma	0.000926	0.0069	CbGeAlD
Maprotiline—Photosensitivity reaction—Temozolomide—malignant glioma	0.000921	0.00864	CcSEcCtD
Maprotiline—Weight increased—Temozolomide—malignant glioma	0.000919	0.00862	CcSEcCtD
Maprotiline—Weight decreased—Temozolomide—malignant glioma	0.000913	0.00857	CcSEcCtD
Maprotiline—Neuropathy peripheral—Carmustine—malignant glioma	0.000913	0.00856	CcSEcCtD
Maprotiline—Stomatitis—Carmustine—malignant glioma	0.000908	0.00852	CcSEcCtD
Maprotiline—SLC6A3—spinal cord—malignant glioma	0.000903	0.00673	CbGeAlD
Maprotiline—Infestation—Temozolomide—malignant glioma	0.0009	0.00844	CcSEcCtD
Maprotiline—Infestation NOS—Temozolomide—malignant glioma	0.0009	0.00844	CcSEcCtD
Maprotiline—HTR2C—midbrain—malignant glioma	0.000895	0.00667	CbGeAlD
Maprotiline—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000892	0.00837	CcSEcCtD
Maprotiline—Neuropathy peripheral—Temozolomide—malignant glioma	0.000882	0.00828	CcSEcCtD
Maprotiline—Stomatitis—Temozolomide—malignant glioma	0.000877	0.00823	CcSEcCtD
Maprotiline—HTR2C—spinal cord—malignant glioma	0.000873	0.00651	CbGeAlD
Maprotiline—Hepatobiliary disease—Temozolomide—malignant glioma	0.000851	0.00798	CcSEcCtD
Maprotiline—CHRM5—brain—malignant glioma	0.00085	0.00633	CbGeAlD
Maprotiline—ABCB1—blood vessel—malignant glioma	0.000844	0.00629	CbGeAlD
Maprotiline—Hypoaesthesia—Carmustine—malignant glioma	0.000832	0.0078	CcSEcCtD
Maprotiline—Hallucination—Carmustine—malignant glioma	0.000832	0.0078	CcSEcCtD
Maprotiline—SLC6A2—medulla oblongata—malignant glioma	0.000817	0.00609	CbGeAlD
Maprotiline—Hepatitis—Temozolomide—malignant glioma	0.000808	0.00758	CcSEcCtD
Maprotiline—Hypoaesthesia—Temozolomide—malignant glioma	0.000804	0.00754	CcSEcCtD
Maprotiline—Hallucination—Temozolomide—malignant glioma	0.000804	0.00754	CcSEcCtD
Maprotiline—Urinary tract disorder—Temozolomide—malignant glioma	0.000798	0.00748	CcSEcCtD
Maprotiline—Urethral disorder—Temozolomide—malignant glioma	0.000792	0.00743	CcSEcCtD
Maprotiline—ORM1—central nervous system—malignant glioma	0.000788	0.00587	CbGeAlD
Maprotiline—HTR7—medulla oblongata—malignant glioma	0.000788	0.00587	CbGeAlD
Maprotiline—Eye disorder—Carmustine—malignant glioma	0.000781	0.00733	CcSEcCtD
Maprotiline—Flushing—Carmustine—malignant glioma	0.000776	0.00728	CcSEcCtD
Maprotiline—HTR2A—embryo—malignant glioma	0.000769	0.00573	CbGeAlD
Maprotiline—Erythema multiforme—Temozolomide—malignant glioma	0.000764	0.00717	CcSEcCtD
Maprotiline—Eye disorder—Temozolomide—malignant glioma	0.000755	0.00708	CcSEcCtD
Maprotiline—Tinnitus—Temozolomide—malignant glioma	0.000753	0.00707	CcSEcCtD
Maprotiline—Flushing—Temozolomide—malignant glioma	0.00075	0.00703	CcSEcCtD
Maprotiline—Cardiac disorder—Temozolomide—malignant glioma	0.00075	0.00703	CcSEcCtD
Maprotiline—HRH1—telencephalon—malignant glioma	0.000748	0.00558	CbGeAlD
Maprotiline—Arrhythmia—Carmustine—malignant glioma	0.000747	0.00701	CcSEcCtD
Maprotiline—Alopecia—Carmustine—malignant glioma	0.000739	0.00693	CcSEcCtD
Maprotiline—CHRM2—central nervous system—malignant glioma	0.000735	0.00548	CbGeAlD
Maprotiline—Angiopathy—Temozolomide—malignant glioma	0.000733	0.00688	CcSEcCtD
Maprotiline—SLC6A3—central nervous system—malignant glioma	0.000733	0.00546	CbGeAlD
Maprotiline—Mediastinal disorder—Temozolomide—malignant glioma	0.000728	0.00683	CcSEcCtD
Maprotiline—Malnutrition—Carmustine—malignant glioma	0.000728	0.00683	CcSEcCtD
Maprotiline—HTR7—midbrain—malignant glioma	0.00072	0.00536	CbGeAlD
Maprotiline—SLC6A3—cerebellum—malignant glioma	0.000716	0.00534	CbGeAlD
Maprotiline—Alopecia—Temozolomide—malignant glioma	0.000714	0.0067	CcSEcCtD
Maprotiline—HTR2C—central nervous system—malignant glioma	0.000708	0.00528	CbGeAlD
Maprotiline—HTR2A—brainstem—malignant glioma	0.000704	0.00525	CbGeAlD
Maprotiline—Malnutrition—Temozolomide—malignant glioma	0.000703	0.0066	CcSEcCtD
Maprotiline—HTR7—spinal cord—malignant glioma	0.000702	0.00523	CbGeAlD
Maprotiline—Dysgeusia—Temozolomide—malignant glioma	0.000689	0.00646	CcSEcCtD
Maprotiline—Vision blurred—Carmustine—malignant glioma	0.000686	0.00643	CcSEcCtD
Maprotiline—Tremor—Carmustine—malignant glioma	0.000682	0.0064	CcSEcCtD
Maprotiline—DRD2—midbrain—malignant glioma	0.000681	0.00507	CbGeAlD
Maprotiline—HTR2A—retina—malignant glioma	0.000679	0.00506	CbGeAlD
Maprotiline—Agitation—Carmustine—malignant glioma	0.000669	0.00627	CcSEcCtD
Maprotiline—CHRM1—central nervous system—malignant glioma	0.000669	0.00498	CbGeAlD
Maprotiline—Vision blurred—Temozolomide—malignant glioma	0.000663	0.00622	CcSEcCtD
Maprotiline—Tremor—Temozolomide—malignant glioma	0.000659	0.00618	CcSEcCtD
Maprotiline—Leukopenia—Carmustine—malignant glioma	0.000651	0.00611	CcSEcCtD
Maprotiline—Agitation—Temozolomide—malignant glioma	0.000646	0.00606	CcSEcCtD
Maprotiline—CYP2D6—brainstem—malignant glioma	0.000642	0.00478	CbGeAlD
Maprotiline—Convulsion—Carmustine—malignant glioma	0.000631	0.00592	CcSEcCtD
Maprotiline—Leukopenia—Temozolomide—malignant glioma	0.00063	0.00591	CcSEcCtD
Maprotiline—Hypertension—Carmustine—malignant glioma	0.000628	0.00589	CcSEcCtD
Maprotiline—HTR2A—telencephalon—malignant glioma	0.000625	0.00466	CbGeAlD
Maprotiline—Palpitations—Temozolomide—malignant glioma	0.000622	0.00583	CcSEcCtD
Maprotiline—Anxiety—Carmustine—malignant glioma	0.000617	0.00579	CcSEcCtD
Maprotiline—Convulsion—Temozolomide—malignant glioma	0.000609	0.00572	CcSEcCtD
Maprotiline—Hypertension—Temozolomide—malignant glioma	0.000607	0.0057	CcSEcCtD
Maprotiline—Confusional state—Carmustine—malignant glioma	0.000599	0.00562	CcSEcCtD
Maprotiline—CHRM3—central nervous system—malignant glioma	0.000599	0.00446	CbGeAlD
Maprotiline—Anxiety—Temozolomide—malignant glioma	0.000597	0.0056	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000595	0.00558	CcSEcCtD
Maprotiline—Oedema—Carmustine—malignant glioma	0.000594	0.00557	CcSEcCtD
Maprotiline—SLC6A2—central nervous system—malignant glioma	0.000591	0.0044	CbGeAlD
Maprotiline—Infection—Carmustine—malignant glioma	0.00059	0.00554	CcSEcCtD
Maprotiline—Dry mouth—Temozolomide—malignant glioma	0.000586	0.00549	CcSEcCtD
Maprotiline—CHRM2—brain—malignant glioma	0.000583	0.00435	CbGeAlD
Maprotiline—SLC6A3—brain—malignant glioma	0.000582	0.00433	CbGeAlD
Maprotiline—Thrombocytopenia—Carmustine—malignant glioma	0.000582	0.00546	CcSEcCtD
Maprotiline—Tachycardia—Carmustine—malignant glioma	0.00058	0.00544	CcSEcCtD
Maprotiline—Confusional state—Temozolomide—malignant glioma	0.000579	0.00543	CcSEcCtD
Maprotiline—Oedema—Temozolomide—malignant glioma	0.000574	0.00538	CcSEcCtD
Maprotiline—Infection—Temozolomide—malignant glioma	0.00057	0.00535	CcSEcCtD
Maprotiline—HTR7—central nervous system—malignant glioma	0.00057	0.00425	CbGeAlD
Maprotiline—CYP2D6—telencephalon—malignant glioma	0.000569	0.00424	CbGeAlD
Maprotiline—Desipramine—CYP2C18—malignant glioma	0.000563	0.0744	CrCbGaD
Maprotiline—Nervous system disorder—Temozolomide—malignant glioma	0.000563	0.00528	CcSEcCtD
Maprotiline—HTR2C—brain—malignant glioma	0.000562	0.00419	CbGeAlD
Maprotiline—Thrombocytopenia—Temozolomide—malignant glioma	0.000562	0.00527	CcSEcCtD
Maprotiline—Skin disorder—Temozolomide—malignant glioma	0.000558	0.00523	CcSEcCtD
Maprotiline—HTR7—cerebellum—malignant glioma	0.000557	0.00415	CbGeAlD
Maprotiline—Hypotension—Carmustine—malignant glioma	0.000555	0.00521	CcSEcCtD
Maprotiline—Hyperhidrosis—Temozolomide—malignant glioma	0.000555	0.00521	CcSEcCtD
Maprotiline—DRD2—central nervous system—malignant glioma	0.000539	0.00401	CbGeAlD
Maprotiline—Insomnia—Carmustine—malignant glioma	0.000537	0.00504	CcSEcCtD
Maprotiline—Paraesthesia—Carmustine—malignant glioma	0.000533	0.005	CcSEcCtD
Maprotiline—CHRM1—brain—malignant glioma	0.000531	0.00396	CbGeAlD
Maprotiline—Somnolence—Carmustine—malignant glioma	0.000528	0.00495	CcSEcCtD
Maprotiline—DRD2—cerebellum—malignant glioma	0.000526	0.00392	CbGeAlD
Maprotiline—Insomnia—Temozolomide—malignant glioma	0.000519	0.00487	CcSEcCtD
Maprotiline—Paraesthesia—Temozolomide—malignant glioma	0.000515	0.00484	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Carmustine—malignant glioma	0.000513	0.00481	CcSEcCtD
Maprotiline—Somnolence—Temozolomide—malignant glioma	0.00051	0.00479	CcSEcCtD
Maprotiline—Constipation—Carmustine—malignant glioma	0.000508	0.00476	CcSEcCtD
Maprotiline—Dyspepsia—Temozolomide—malignant glioma	0.000505	0.00474	CcSEcCtD
Maprotiline—ABCB1—embryo—malignant glioma	0.000504	0.00375	CbGeAlD
Maprotiline—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000496	0.00465	CcSEcCtD
Maprotiline—Atomoxetine—SLC6A3—malignant glioma	0.000495	0.0654	CrCbGaD
Maprotiline—Fatigue—Temozolomide—malignant glioma	0.000495	0.00464	CcSEcCtD
Maprotiline—HTR2A—medulla oblongata—malignant glioma	0.000491	0.00366	CbGeAlD
Maprotiline—Constipation—Temozolomide—malignant glioma	0.000491	0.0046	CcSEcCtD
Maprotiline—Feeling abnormal—Carmustine—malignant glioma	0.000489	0.00459	CcSEcCtD
Maprotiline—Gastrointestinal pain—Carmustine—malignant glioma	0.000486	0.00456	CcSEcCtD
Maprotiline—Imipramine—CYP2C18—malignant glioma	0.000478	0.0631	CrCbGaD
Maprotiline—CHRM3—brain—malignant glioma	0.000475	0.00354	CbGeAlD
Maprotiline—Feeling abnormal—Temozolomide—malignant glioma	0.000473	0.00444	CcSEcCtD
Maprotiline—Abdominal pain—Carmustine—malignant glioma	0.00047	0.0044	CcSEcCtD
Maprotiline—Body temperature increased—Carmustine—malignant glioma	0.00047	0.0044	CcSEcCtD
Maprotiline—Gastrointestinal pain—Temozolomide—malignant glioma	0.000469	0.0044	CcSEcCtD
Maprotiline—SLC6A2—brain—malignant glioma	0.000469	0.0035	CbGeAlD
Maprotiline—Urticaria—Temozolomide—malignant glioma	0.000456	0.00428	CcSEcCtD
Maprotiline—Abdominal pain—Temozolomide—malignant glioma	0.000454	0.00426	CcSEcCtD
Maprotiline—Body temperature increased—Temozolomide—malignant glioma	0.000454	0.00426	CcSEcCtD
Maprotiline—HTR7—brain—malignant glioma	0.000452	0.00337	CbGeAlD
Maprotiline—HTR2A—midbrain—malignant glioma	0.000449	0.00334	CbGeAlD
Maprotiline—ABCB1—retina—malignant glioma	0.000445	0.00332	CbGeAlD
Maprotiline—HTR2A—spinal cord—malignant glioma	0.000438	0.00326	CbGeAlD
Maprotiline—DRD2—brain—malignant glioma	0.000428	0.00319	CbGeAlD
Maprotiline—Asthenia—Carmustine—malignant glioma	0.000426	0.004	CcSEcCtD
Maprotiline—HRH1—central nervous system—malignant glioma	0.000425	0.00317	CbGeAlD
Maprotiline—Desipramine—CYP2B6—malignant glioma	0.000418	0.0552	CrCbGaD
Maprotiline—Asthenia—Temozolomide—malignant glioma	0.000412	0.00386	CcSEcCtD
Maprotiline—ABCB1—telencephalon—malignant glioma	0.00041	0.00305	CbGeAlD
Maprotiline—Diarrhoea—Carmustine—malignant glioma	0.000406	0.00381	CcSEcCtD
Maprotiline—Pruritus—Temozolomide—malignant glioma	0.000406	0.00381	CcSEcCtD
Maprotiline—Dizziness—Carmustine—malignant glioma	0.000393	0.00368	CcSEcCtD
Maprotiline—Diarrhoea—Temozolomide—malignant glioma	0.000393	0.00368	CcSEcCtD
Maprotiline—Dizziness—Temozolomide—malignant glioma	0.00038	0.00356	CcSEcCtD
Maprotiline—Vomiting—Carmustine—malignant glioma	0.000378	0.00354	CcSEcCtD
Maprotiline—Rash—Carmustine—malignant glioma	0.000375	0.00351	CcSEcCtD
Maprotiline—Dermatitis—Carmustine—malignant glioma	0.000374	0.00351	CcSEcCtD
Maprotiline—Headache—Carmustine—malignant glioma	0.000372	0.00349	CcSEcCtD
Maprotiline—Vomiting—Temozolomide—malignant glioma	0.000365	0.00342	CcSEcCtD
Maprotiline—Rash—Temozolomide—malignant glioma	0.000362	0.0034	CcSEcCtD
Maprotiline—Dermatitis—Temozolomide—malignant glioma	0.000362	0.00339	CcSEcCtD
Maprotiline—Headache—Temozolomide—malignant glioma	0.00036	0.00337	CcSEcCtD
Maprotiline—Desipramine—SLC6A3—malignant glioma	0.000356	0.047	CrCbGaD
Maprotiline—HTR2A—central nervous system—malignant glioma	0.000355	0.00265	CbGeAlD
Maprotiline—Imipramine—CYP2B6—malignant glioma	0.000355	0.0468	CrCbGaD
Maprotiline—Nausea—Carmustine—malignant glioma	0.000353	0.00331	CcSEcCtD
Maprotiline—HTR2A—cerebellum—malignant glioma	0.000347	0.00259	CbGeAlD
Maprotiline—Nausea—Temozolomide—malignant glioma	0.000341	0.0032	CcSEcCtD
Maprotiline—HRH1—brain—malignant glioma	0.000338	0.00252	CbGeAlD
Maprotiline—Nortriptyline—PTGS1—malignant glioma	0.000334	0.0441	CrCbGaD
Maprotiline—CYP2D6—central nervous system—malignant glioma	0.000324	0.00241	CbGeAlD
Maprotiline—ABCB1—medulla oblongata—malignant glioma	0.000322	0.0024	CbGeAlD
Maprotiline—CYP2D6—cerebellum—malignant glioma	0.000316	0.00236	CbGeAlD
Maprotiline—Imipramine—SLC6A3—malignant glioma	0.000302	0.0399	CrCbGaD
Maprotiline—ABCB1—midbrain—malignant glioma	0.000294	0.00219	CbGeAlD
Maprotiline—ABCB1—spinal cord—malignant glioma	0.000287	0.00214	CbGeAlD
Maprotiline—HTR2A—brain—malignant glioma	0.000282	0.0021	CbGeAlD
Maprotiline—CYP2D6—brain—malignant glioma	0.000257	0.00191	CbGeAlD
Maprotiline—ABCB1—central nervous system—malignant glioma	0.000233	0.00173	CbGeAlD
Maprotiline—ABCB1—cerebellum—malignant glioma	0.000228	0.0017	CbGeAlD
Maprotiline—ABCB1—brain—malignant glioma	0.000185	0.00138	CbGeAlD
Maprotiline—HTR2C—Signaling Pathways—FGF2—malignant glioma	7.87e-06	9.88e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTPN11—malignant glioma	7.83e-06	9.83e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—BRAF—malignant glioma	7.75e-06	9.74e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NCOR1—malignant glioma	7.75e-06	9.73e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—AKT1—malignant glioma	7.73e-06	9.71e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MMP9—malignant glioma	7.63e-06	9.59e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—BRAF—malignant glioma	7.63e-06	9.58e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—BRAF—malignant glioma	7.61e-06	9.56e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PTEN—malignant glioma	7.59e-06	9.54e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—BRAF—malignant glioma	7.59e-06	9.53e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—VEGFA—malignant glioma	7.58e-06	9.52e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—BRAF—malignant glioma	7.56e-06	9.5e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT2—malignant glioma	7.55e-06	9.48e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—EGFR—malignant glioma	7.51e-06	9.44e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—STAT3—malignant glioma	7.51e-06	9.43e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—BRAF—malignant glioma	7.49e-06	9.41e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT2—malignant glioma	7.42e-06	9.33e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT2—malignant glioma	7.41e-06	9.31e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—AKT1—malignant glioma	7.4e-06	9.3e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—EGFR—malignant glioma	7.39e-06	9.29e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	7.39e-06	9.28e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT2—malignant glioma	7.38e-06	9.28e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—malignant glioma	7.38e-06	9.27e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CB—malignant glioma	7.37e-06	9.26e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT2—malignant glioma	7.36e-06	9.25e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MDM2—malignant glioma	7.36e-06	9.25e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—malignant glioma	7.35e-06	9.24e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—RAF1—malignant glioma	7.33e-06	9.21e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—malignant glioma	7.33e-06	9.21e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—malignant glioma	7.3e-06	9.18e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT2—malignant glioma	7.29e-06	9.16e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—malignant glioma	7.26e-06	9.12e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—ERBB2—malignant glioma	7.26e-06	9.12e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CD—malignant glioma	7.25e-06	9.11e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.25e-06	9.1e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—PIK3CA—malignant glioma	7.18e-06	9.02e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	7.16e-06	9e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—malignant glioma	7.16e-06	8.99e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTP1—malignant glioma	7.14e-06	8.97e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	7.13e-06	8.96e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CD—malignant glioma	7.12e-06	8.94e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—KRAS—malignant glioma	7.1e-06	8.92e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CD—malignant glioma	7.1e-06	8.91e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—STAT3—malignant glioma	7.09e-06	8.91e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CD—malignant glioma	7.07e-06	8.89e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	7.07e-06	8.88e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—PIK3CA—malignant glioma	7.05e-06	8.86e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—PIK3CA—malignant glioma	7.03e-06	8.83e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—PIK3CA—malignant glioma	7.01e-06	8.8e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CD—malignant glioma	7e-06	8.8e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—malignant glioma	6.98e-06	8.77e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—malignant glioma	6.97e-06	8.76e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—malignant glioma	6.97e-06	8.76e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAT—malignant glioma	6.95e-06	8.73e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—malignant glioma	6.95e-06	8.73e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—FGF2—malignant glioma	6.94e-06	8.72e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—PIK3CA—malignant glioma	6.94e-06	8.72e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—malignant glioma	6.92e-06	8.7e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CXCL8—malignant glioma	6.88e-06	8.65e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—malignant glioma	6.86e-06	8.62e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—malignant glioma	6.86e-06	8.61e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—FGF2—malignant glioma	6.83e-06	8.58e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—malignant glioma	6.82e-06	8.57e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—FGF2—malignant glioma	6.82e-06	8.56e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—FGF2—malignant glioma	6.79e-06	8.54e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—STAT3—malignant glioma	6.79e-06	8.53e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—FGF2—malignant glioma	6.77e-06	8.51e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—FGF2—malignant glioma	6.71e-06	8.43e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CAV1—malignant glioma	6.7e-06	8.42e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	6.65e-06	8.35e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—malignant glioma	6.59e-06	8.28e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CASP3—malignant glioma	6.59e-06	8.27e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL2—malignant glioma	6.58e-06	8.26e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NCOR1—malignant glioma	6.56e-06	8.25e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	6.52e-06	8.19e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MDM2—malignant glioma	6.49e-06	8.16e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—RAF1—malignant glioma	6.47e-06	8.13e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—malignant glioma	6.44e-06	8.1e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—malignant glioma	6.44e-06	8.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	6.42e-06	8.06e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ERBB2—malignant glioma	6.4e-06	8.05e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—malignant glioma	6.4e-06	8.04e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MDM2—malignant glioma	6.39e-06	8.03e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—malignant glioma	6.38e-06	8.02e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MDM2—malignant glioma	6.38e-06	8.01e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—malignant glioma	6.37e-06	8e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—RAF1—malignant glioma	6.37e-06	8e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—malignant glioma	6.36e-06	7.99e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MDM2—malignant glioma	6.36e-06	7.99e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—RAF1—malignant glioma	6.35e-06	7.98e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MDM2—malignant glioma	6.34e-06	7.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—RAF1—malignant glioma	6.33e-06	7.96e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—malignant glioma	6.32e-06	7.94e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAV1—malignant glioma	6.32e-06	7.94e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—RAF1—malignant glioma	6.31e-06	7.93e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—malignant glioma	6.31e-06	7.92e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ERBB2—malignant glioma	6.3e-06	7.92e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—malignant glioma	6.3e-06	7.92e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ERBB2—malignant glioma	6.29e-06	7.9e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MDM2—malignant glioma	6.27e-06	7.88e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ERBB2—malignant glioma	6.27e-06	7.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—RAF1—malignant glioma	6.25e-06	7.86e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ERBB2—malignant glioma	6.25e-06	7.85e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.22e-06	7.82e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	6.22e-06	7.81e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—malignant glioma	6.2e-06	7.8e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.19e-06	7.77e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ERBB2—malignant glioma	6.19e-06	7.77e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	6.18e-06	7.77e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—malignant glioma	6.17e-06	7.75e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—malignant glioma	6.16e-06	7.75e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—malignant glioma	6.1e-06	7.67e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—malignant glioma	6.1e-06	7.67e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—malignant glioma	6.09e-06	7.65e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—malignant glioma	6.07e-06	7.63e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.04e-06	7.58e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—malignant glioma	5.97e-06	7.51e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—malignant glioma	5.96e-06	7.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—malignant glioma	5.94e-06	7.47e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—malignant glioma	5.92e-06	7.44e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—malignant glioma	5.92e-06	7.44e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—malignant glioma	5.89e-06	7.4e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—malignant glioma	5.87e-06	7.37e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—malignant glioma	5.87e-06	7.37e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—malignant glioma	5.83e-06	7.32e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—malignant glioma	5.81e-06	7.3e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL2—malignant glioma	5.8e-06	7.29e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	5.77e-06	7.25e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—malignant glioma	5.76e-06	7.24e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—malignant glioma	5.75e-06	7.23e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	5.74e-06	7.21e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—malignant glioma	5.73e-06	7.2e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—malignant glioma	5.72e-06	7.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—malignant glioma	5.72e-06	7.19e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL2—malignant glioma	5.71e-06	7.17e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—malignant glioma	5.71e-06	7.17e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL2—malignant glioma	5.7e-06	7.16e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—malignant glioma	5.69e-06	7.15e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL2—malignant glioma	5.68e-06	7.14e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—malignant glioma	5.67e-06	7.12e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—malignant glioma	5.67e-06	7.12e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL2—malignant glioma	5.66e-06	7.11e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—malignant glioma	5.61e-06	7.05e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL2—malignant glioma	5.61e-06	7.04e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—malignant glioma	5.59e-06	7.02e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.59e-06	7.02e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—malignant glioma	5.55e-06	6.98e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.53e-06	6.95e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—malignant glioma	5.49e-06	6.9e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—malignant glioma	5.46e-06	6.86e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—malignant glioma	5.41e-06	6.8e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—malignant glioma	5.4e-06	6.79e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—malignant glioma	5.39e-06	6.78e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—malignant glioma	5.38e-06	6.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—malignant glioma	5.37e-06	6.75e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—malignant glioma	5.37e-06	6.74e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—malignant glioma	5.36e-06	6.74e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—malignant glioma	5.36e-06	6.73e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—malignant glioma	5.35e-06	6.73e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAV1—malignant glioma	5.35e-06	6.72e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—malignant glioma	5.34e-06	6.71e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—malignant glioma	5.33e-06	6.69e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—malignant glioma	5.33e-06	6.69e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—malignant glioma	5.31e-06	6.67e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—malignant glioma	5.28e-06	6.63e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.24e-06	6.59e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—malignant glioma	5.23e-06	6.57e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—malignant glioma	5.21e-06	6.55e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—malignant glioma	5.2e-06	6.53e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—malignant glioma	5.18e-06	6.51e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—malignant glioma	5.15e-06	6.47e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—malignant glioma	5.14e-06	6.46e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.11e-06	6.42e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.06e-06	6.35e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.03e-06	6.32e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—malignant glioma	4.93e-06	6.2e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—malignant glioma	4.88e-06	6.14e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—malignant glioma	4.87e-06	6.12e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—malignant glioma	4.85e-06	6.1e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—malignant glioma	4.84e-06	6.08e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—malignant glioma	4.84e-06	6.08e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—malignant glioma	4.83e-06	6.06e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—malignant glioma	4.81e-06	6.05e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—malignant glioma	4.8e-06	6.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—malignant glioma	4.79e-06	6.02e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—malignant glioma	4.78e-06	6e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—malignant glioma	4.76e-06	5.99e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—malignant glioma	4.76e-06	5.99e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.75e-06	5.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—malignant glioma	4.72e-06	5.93e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—malignant glioma	4.7e-06	5.91e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—malignant glioma	4.68e-06	5.88e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—malignant glioma	4.64e-06	5.82e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—malignant glioma	4.57e-06	5.74e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—malignant glioma	4.54e-06	5.7e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—malignant glioma	4.49e-06	5.65e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—malignant glioma	4.46e-06	5.61e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—malignant glioma	4.46e-06	5.6e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—malignant glioma	4.44e-06	5.58e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—malignant glioma	4.44e-06	5.58e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—malignant glioma	4.43e-06	5.56e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.41e-06	5.54e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—malignant glioma	4.38e-06	5.51e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—malignant glioma	4.37e-06	5.5e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—malignant glioma	4.37e-06	5.49e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.37e-06	5.49e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.36e-06	5.48e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—malignant glioma	4.36e-06	5.48e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—malignant glioma	4.34e-06	5.46e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—malignant glioma	4.33e-06	5.44e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—malignant glioma	4.29e-06	5.39e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—malignant glioma	4.28e-06	5.38e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—malignant glioma	4.22e-06	5.31e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—malignant glioma	4.19e-06	5.27e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.13e-06	5.18e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—malignant glioma	4.12e-06	5.17e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—malignant glioma	4.1e-06	5.16e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—malignant glioma	4.09e-06	5.14e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—malignant glioma	4.05e-06	5.09e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—malignant glioma	4.04e-06	5.08e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—malignant glioma	3.85e-06	4.84e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—malignant glioma	3.81e-06	4.79e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.79e-06	4.76e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—malignant glioma	3.78e-06	4.75e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	3.77e-06	4.74e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—malignant glioma	3.76e-06	4.72e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—malignant glioma	3.73e-06	4.69e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—malignant glioma	3.73e-06	4.68e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—malignant glioma	3.72e-06	4.68e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—malignant glioma	3.7e-06	4.65e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—malignant glioma	3.67e-06	4.61e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—malignant glioma	3.67e-06	4.61e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—malignant glioma	3.66e-06	4.6e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—malignant glioma	3.65e-06	4.58e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—malignant glioma	3.64e-06	4.57e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—malignant glioma	3.6e-06	4.52e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.57e-06	4.48e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—malignant glioma	3.23e-06	4.05e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—malignant glioma	3.15e-06	3.95e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.1e-06	3.89e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—malignant glioma	3.09e-06	3.88e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—malignant glioma	3.08e-06	3.87e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—malignant glioma	3.07e-06	3.86e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—malignant glioma	3.04e-06	3.82e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—malignant glioma	2.85e-06	3.58e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.69e-06	3.38e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—malignant glioma	2.33e-06	2.93e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—malignant glioma	2.28e-06	2.86e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—malignant glioma	2.2e-06	2.76e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—malignant glioma	1.86e-06	2.34e-05	CbGpPWpGaD
